Medtech Investment Outlook: In Health Care You Don’t Become A Unicorn Overnight
Executive Summary
The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.
You may also be interested in...
Pandemic Perspectives: Riding The Waves Of Asia’s Healthtech Innovation Explosion
One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.
China Market Growth Spurs Siemens Healthineers To Restructure Asia Ops
Germany-headquartered Siemens Healthineers has uncoupled China from the rest of its Asia business to maximize opportunities in the world’s largest medtech market-in-waiting.
Putting The E In ESG: A Global Medtech’s Approach To Meeting The Climate Challenge
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.